Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies[J]. Cancer Treat Rev, 2001, 27(3): 165-176.
[4]
Weinfurt KP, Li Y, Castel LD, et al. The impact of skeletal of life of patients with metastatic prostate cancer[J]. Ann Oncol, 2002, 13(Suppl 5): 180.
[5]
Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints[J]. Am J Clin Oncol, 2002, 25(Suppl 1): 10-18.
[6]
Tyrrell CJ. Role of pamidronate in the management of bone metases from breast cancer[J]. Ann Oncol, 1994, 5(Suppl 7): 37.
[7]
Coxon FP, Rogers MJ. The role of prenylated small GTP binding proteins in regulation of osteoclast function[J]. Calcif Tissue Int, 2003, 72(1): 80-84.
[8]
Benford HL, McGowan NW, Helfich MH, et al. Visualization of bisphosphonate-induced caspase-3 active in apoptotic osteoclasts in vitro[J]. Bone, 2001, 28(5): 465-473.
[9]
Monkkonen H, Lehenkari PP, Kellinsalmi M, et al. A new mechanism of action for bisphosphonates appidedicated cytotoxicty of N-BPs[J]. Bone, 2004, 34(Suppl 1): S66-S67.
[10]
Rogers MJ. New insights in to the molecular mechanism of action of bisphospbonates[J]. Curr Pharm Des, 2003, 9(32): 2643-2658.
[11]
van Beek ER, Cohen LH, Leroy JM, et al. Different the mechanism of an tiresorptive action of nitrogen containing bisphosphonate[J]. Bone, 2003, 33(5): 805-811.
[12]
Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid[J]. JCO, 2005, 23(22): 4925-4935.
Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion[J]. Cancer, 2004, 100(1): 36-43.
